Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 | Q16539 | 16/20 | 1.00 |
| ▸ | MAPK13 | O15264 | 15/20 | 1.00 |
| ▸ | MAPK12 | P53778 | 15/20 | 1.00 |
| ▸ | MAPK11 | Q15759 | 15/20 | 1.00 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | TP53 | P04637 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29432589 | 1.00 | MAPK14 (1.00) | MAPK14MAPK13MAPK12MAPK11MAPT | |
| SCHEMBL6394499 | 0.91 | MAPK14 (0.84) | MAPK14MAPK13MAPK12MAPK11MAPT | |
| SCHEMBL6394890 | 0.91 | MAPK14 (0.84) | MAPK14MAPK13MAPK12MAPK11MAPT | |
| SCHEMBL1906604 | 0.90 | MAPK14 (0.81) | MAPK14MAPK13MAPK12MAPK11MAPT | |
| SCHEMBL1906530 | 0.90 | MAPK14 (0.81) | MAPK14MAPK13MAPK12MAPK11MAPT | |
| SCHEMBL6397468 | 0.89 | MAPK14 (0.80) | MAPK14MAPK13MAPK12MAPK11MAPT | |
| SCHEMBL7211089 | 0.89 | MAPK14 (0.80) | MAPK14MAPK13MAPK12MAPK11MAPT | |
| SCHEMBL6655830 | 0.89 | MAPK14 (0.80) | MAPK14MAPK13MAPK12MAPK11MAPT | |
| SCHEMBL6395572 | 0.88 | MAPK14 (0.78) | MAPK14MAPK13MAPK12MAPK11MAPT | |
| SCHEMBL6396535 | 0.88 | MAPK14 (0.78) | MAPK14MAPK13MAPK12MAPK11MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 108 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200237728-A1 | CHEMOTHERAPEUTIC METHODS | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED | 2020-07-30 | — | — | US | claimed |
| EP-1202954-B1 | NOVEL AMINOBENZOPHENONES | LEO PHARMA AS (DK) | 2003-10-01 | — | — | EP | claimed |
| US-6624199-B1 | Prophylaxis and treatment of acne and acne related skin diseases with aminobenzophenones, and novel compounds effective in the treatment, as well as pharmaceutical preparations containing these compounds and dosage units | LEO PHARMACEUTICALS PRODUCTS LTD. A/S (DK) | 2003-09-23 | — | — | US | claimed |
| US-20020165286-A1 | Dermal anti-inflammatory composition | LEO PHARMACEUTICAL PRODUCTS LTD. A/S (DK) | 2002-11-07 | — | — | US | claimed |
| WO-2002045752-A2 | DERMAL ANTI-INFLAMMATORY COMPOSITION | LEO PHARMA A/S (DK) | 2002-06-13 | — | — | WO | claimed |
| EP-1202954-A1 | NOVEL AMINOBENZOPHENONES | LEO PHARMACEUTICAL PRODUCTS LTD. A/S (LOVENS KEMISKE FABRIK PRODUKTIONSAKTIESELSKAB) (DK) | 2002-05-08 | — | — | EP | claimed |
| WO-2001005744-A1 | NOVEL AMINOBENZOPHENONES | Leo Pharmaceutical Products Ltd. A/S (Løvens Kemiske Fabrik Produktionsaktieselskab) (DK) | 2001-01-25 | — | — | WO | claimed |
| US-20260115177-A1 | MEDICINAL PRODUCTS AND METHODS FOR THE ALLEVIATION OF CANCER IMMUNOTHERA-PY-ASSOCIATED CYTOKINE RELEASE SYNDROME | POOLBEG PHARMA UK LTD (GB) | 2026-04-30 | — | — | US | disclosed |
| EP-4709405-A2 | FLUORESCEIN-LABELED NERVE TARGETING PEPTIDE FORMULATIONS AND RELATED METHODS | Alume Biosciences, Inc. (US) | 2026-03-18 | — | — | EP | disclosed |
| US-12533425-B2 | Methods and systems using peptides for targeting and mapping human nerves in image guided surgery, diagnostics and therapeutic delivery | ALUME BIOSCIENCES, INC. (US) | 2026-01-27 | — | — | US | disclosed |
| EP-4648772-A1 | MEDICINAL PRODUCTS AND METHODS FOR THE ALLEVIATION OF CANCER IMMUNOTHERAPY-ASSOCIATED CYTOKINE RELEASE SYNDROME | Poolbeg Pharma (UK) Limited (GB) | 2025-11-19 | — | — | EP | disclosed |
| EP-4484952-A2 | OPTIMIZED PEPTIDES FOR TARGETING HUMAN NERVES AND THEIR USE IN IMAGE GUIDED SURGERY, DIAGNOSTICS AND THERAPEUTIC DELIVERY | The Regents of the University of California (US) | 2025-01-01 | — | — | EP | disclosed |
| WO-2024233683-A2 | FLUORESCEIN-LABELED NERVE TARGETING PEPTIDE FORMULATIONS AND RELATED METHODS | ALUME BIOSCIENCES, INC. (US) | 2024-11-14 | — | — | WO | disclosed |
| WO-2002045752-A2 | DERMAL ANTI-INFLAMMATORY COMPOSITION | LEO PHARMA A/S (DK) | 2002-06-13 | — | — | WO | disclosed |
| EP-1210325-A1 | AMINOBENZOPHENONES AS INHIBITORS OF IL-1BETA AND TNF-ALPHA | LEO PHARMACEUTICAL PRODUCTS LTD. A/S (LOVENS KEMISKE FABRIK PRODUKTIONSAKTIESELSKAB) (DK) | 2002-06-05 | — | — | EP | disclosed |
| EP-1202954-A1 | NOVEL AMINOBENZOPHENONES | LEO PHARMACEUTICAL PRODUCTS LTD. A/S (LOVENS KEMISKE FABRIK PRODUKTIONSAKTIESELSKAB) (DK) | 2002-05-08 | — | — | EP | disclosed |
| EP-1202957-A1 | AMINOBENZOPHENONES AS INHIBITORS OF IL-1BETA AND TNF-ALPHA | LEO PHARMACEUTICAL PRODUCTS LTD. A/S (LOVENS KEMISKE FABRIK PRODUKTIONSAKTIESELSKAB) (DK) | 2002-05-08 | — | — | EP | disclosed |
| WO-2001005745-A1 | AMINOBENZOPHENONES AS INHIBITORS OF IL-1β AND TNF-$g(a) | Leo Pharmaceutical Products Ltd. A/S (Løvens Kemiske Fabrik Produktionsaktieselskab) (DK) | 2001-01-25 | — | — | WO | disclosed |
| WO-2001005744-A1 | NOVEL AMINOBENZOPHENONES | Leo Pharmaceutical Products Ltd. A/S (Løvens Kemiske Fabrik Produktionsaktieselskab) (DK) | 2001-01-25 | — | — | WO | disclosed |
| WO-2001005751-A1 | AMINOBENZOPHENONES AS INHIBITORS OF IL-1β AND TNF-$g(a) | Leo Pharmaceutical Products Ltd. A/S (Løvens Kemiske Fabrik Produktionsaktieselskab) (DK) | 2001-01-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12533425-B2 | Methods and systems using peptides for targeting and mapping human nerves in image guided surgery, diagnostics and therapeutic delivery | NGLY1, VGF, GAP43 | MAPK14 2042/4885MAPK13 1071/4885MAPK12 587/4885 |
| US-20020165286-A1 | Dermal anti-inflammatory composition | CUTA, IL1B, LRBA | MAPK14 644/4885MAPK13 1521/4885MAPK12 1535/4885 |
| US-20260115177-A1 | MEDICINAL PRODUCTS AND METHODS FOR THE ALLEVIATION OF CANCER IMMUNOTHERA-PY-ASSOCIATED CYTOKINE RELEASE SYNDROME | MAPK13, MAPK11, MAPK1 | MAPK14 18/4885MAPK13 1/4885MAPK12 5/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.